Chronic Headaches: Migraine, Medication Overuse and 2026 Prevention Guidelines

Evidence and references reviewed: 10 November 2026.

Frequent headaches require a specific diagnosis and a plan for both attacks and prevention. Migraine, tension-type headache, cluster headache and secondary causes should not be treated as interchangeable conditions.

Check for warning signs

Sudden headache reaching peak intensity within minutes, a new neurological deficit, worsening headache with fever or new cognitive changes needs prompt assessment. Do not assume a new or substantially different headache is simply another migraine.1

Different headache syndromes need different treatment

Headache syndrome Typical pattern Management implications
Migraine Recurrent moderate/severe headaches, often with nausea, light/sound sensitivity, activity aggravation and sometimes aura. Attack-specific treatment and prevention when indicated.
Tension-type headache Usually bilateral pressing or tightening pain without prominent migrainous symptoms. Education, appropriate simple analgesics and avoiding medication overuse.
Cluster headache Severe strictly unilateral orbital or temporal attacks with tearing, nasal congestion or restlessness, often in clusters. Specialist acute oxygen or subcutaneous triptan; preventive strategies differ.
Medication-overuse headache Frequent headaches alongside regular overuse of acute medicines. Review all rescue medicines, plan withdrawal and treat the underlying headache disorder.
Secondary headache New thunderclap onset, fever, neurologic signs, pregnancy-related change or other concerning findings. Urgent targeted investigation, not simply stronger pain medicine.

Headache classification requires the pattern over time and associated clinical findings, not just where pain is felt. Patients with recurring headaches benefit from a headache diary recording frequency, severity, duration, triggers, medication days and disability.1,2

What is chronic migraine?

ICHD-3 requires headache on at least 15 days per month for more than three months, with migraine features or qualifying migraine treatment response on at least eight days per month, in a patient with the relevant migraine history. Other explanations must be considered. Fifteen headache days alone do not establish chronic migraine.2

Medication-overuse headache can coexist

Medication-overuse headache involves at least 15 headache days monthly and regular overuse of acute medication for more than three months. Both chronic migraine and medication-overuse headache may be diagnosed. Record the names and days of use of all rescue medicines; alternating brands can conceal cumulative exposure.3

NICE identifies overuse thresholds of at least ten days monthly for triptans, opioids, ergots or combination analgesics, and fifteen for paracetamol, aspirin or NSAIDs. Withdrawal and follow-up should be planned; dependence-forming medicines need particular care.1

Acute treatment is different from prevention

For migraine attacks, NICE recommends a triptan with an NSAID or paracetamol, or suitable monotherapy according to preferences and contraindications. Paracetamol is a simple analgesic, not an NSAID. Opioids and ergots are not recommended as routine acute migraine treatment.1

Sumatriptan activates serotonin 5-HT1B/1D receptors and treats attacks rather than preventing them. Its contraindications include coronary artery disease, previous stroke or TIA and uncontrolled hypertension. It must not be used within 24 hours of another triptan or an ergot, or with recent MAO-A inhibitor exposure. Dose limits and repeat intervals are product-specific; a class-wide redosing rule is unsafe.4

For tension-type attacks, paracetamol or an appropriate NSAID may help; opioids are not recommended.1

When should prevention be discussed?

Under the 2026 joint American Academy of Neurology (AAN)–American Headache Society (AHS) guideline, clinicians should offer migraine preventive treatment to individuals with at least four migraine days per month or at least four moderate-to-severe headache days per month; prevention is also appropriate when migraine causes substantial disability. The decision should reflect patient preference, access, medication tolerance, comorbidity and goals.11

Preventive therapy is not an admission that acute medicines failed. Its purpose is to reduce attack frequency, disability, acute drug use and risk of medication overuse. Some patients with fewer attacks but unusually disabling episodes may still benefit from an individualized preventive strategy.

Choosing preventive treatment

NICE lists propranolol, topiramate and amitriptyline as options and advises against gabapentin for migraine prevention. Selection depends on comorbidity, tolerability and reproductive considerations.1

The American Headache Society’s 2024 position recognises CGRP-targeting therapies as first-line preventive options without requiring failure of older treatments. This includes certain monoclonal antibodies and gepants. Local reimbursement or national pathways may nevertheless impose different access criteria; a clinical recommendation is not a guarantee of availability.5

OnabotulinumtoxinA is another option for selected adults with chronic migraine after preventive treatment failures and appropriate management of medication overuse.1

2026 AAN/AHS update: evidence-based preventive choices

The August 31, 2026 AAN/AHS joint guideline evaluated randomized trials of adult migraine preventive treatments and supports individualized selection of several effective drug classes, including CGRP pathway inhibitors, established oral preventives and onabotulinumtoxinA in chronic migraine, as appropriate. It offers a current framework in addition to the earlier 2024 AHS position on CGRP-targeted drugs.11

Preventive option Examples Practical issue
Beta blockers Propranolol and selected alternatives Consider pulse, blood pressure, asthma and exercise tolerance.
Antiseizure medicines Topiramate; valproate only after stringent reproductive-risk review Topiramate and valproate have major pregnancy-related risks.
Tricyclic antidepressants Amitriptyline Sleep benefit in selected people; sedation, anticholinergic and cardiac effects.
CGRP monoclonal antibodies Erenumab, fremanezumab, galcanezumab, eptinezumab Route and dosing differ; cost/access and adverse effects matter.
Preventive gepants Atogepant; rimegepant for indicated episodic prevention CYP and transporter interactions and indication-specific schedules.
OnabotulinumtoxinA Clinician-administered injections For selected chronic migraine, not routine treatment of every tension headache.

Drug classes are not automatically equivalent, and a favorable guideline recommendation does not guarantee an agent is appropriate in pregnancy, severe kidney disease, significant cardiac illness or a country where it is unlicensed. Some patients benefit most from combining prevention with sleep, regular meals, hydration, stress management and behavioral therapies.1,11

Routes and schedules are not interchangeable

Medicine Role and route Schedule distinction
Atogepant Oral CGRP-receptor antagonist for adult migraine prevention Taken daily; dose selection depends on migraine type, interactions and organ function.6
Rimegepant Orally disintegrating CGRP-receptor antagonist Used as needed for attacks or every other day for prevention of episodic migraine, following the label.7
Eptinezumab CGRP-targeting monoclonal antibody for adult prevention Intravenous infusion every three months, not intramuscular injection.8

Gepants are not free of interactions. Rimegepant has clinically important CYP3A and P-glycoprotein interaction restrictions. Strong CYP3A inhibitors or inducers can make a regimen inappropriate; some other interacting medicines require longer intervals between doses. Check the individual label rather than applying antibody pharmacokinetics to oral gepants.7

Cluster headache needs a different approach

Guideline-supported attack treatments include high-flow oxygen and subcutaneous sumatriptan. Verapamil is an established preventive option requiring ECG monitoring during dose escalation. Lithium is a specialist alternative with serum-level monitoring; it should not be presented as routine treatment for chronic migraine. Short-term corticosteroids may be used as transitional cluster treatment under supervision.9

Medication-overuse headache: prevention and withdrawal together

The 2026 AAN/AHS guideline recommends offering preventive medication to eligible patients with medication overuse or established medication-overuse headache. Agents with evidence in this setting—including selected CGRP-directed treatments, topiramate and onabotulinumtoxinA—may be considered before drugs without such evidence.11

Withdrawal of the overused acute agent often forms part of care; the method depends on what was used. Triptans and simple analgesics are handled differently from opioids or barbiturate-containing medicines, which may need supervised tapering and specialist support. Do not abruptly stop dependence-forming agents based on an online list. A headache diary documents headache days and acute-medication days to judge response.

Pregnancy and treatment review

Topiramate must not be used for migraine prevention during pregnancy. UK MHRA requirements also include a Pregnancy Prevention Programme for people who could become pregnant, with effective contraception and regular review. Potential fetal harms include congenital malformations, low birth weight and possible neurodevelopmental effects. Use current safety guidance rather than obsolete pregnancy-letter categories.10

A useful review documents headache days, migraine days, acute-medicine days, functional impact and adverse effects. Revisit the diagnosis and regimen when response is poor, rather than escalating rescue medicines indefinitely.

When should follow-up change the plan?

Review monthly migraine days, severe headache days, medication-overuse days, work or school impact, sleep and treatment adverse effects. Patients may need adjustment if a trial has not provided meaningful benefit after a suitable period, or if pregnancy plans, kidney function, vascular risk or other medications change. The goal is improved function and fewer disabling attacks, not simply prescription of the newest drug.

Frequently asked questions

How many headaches define chronic migraine?

At least 15 headache days per month for over three months, with migraine features or qualifying migraine treatment on at least eight days, plus the specified diagnostic history.2

When should migraine prevention be offered?

The 2026 AAN/AHS guideline recommends offering it at four or more migraine days per month, or with substantial migraine disability.11

Can frequent triptan use make headaches worse?

Yes. Regular use on at least 10 days monthly for over three months can meet medication-overuse thresholds in the appropriate clinical context.3

Is onabotulinumtoxinA used for all headache types?

No. Its established preventive role is mainly in selected adults with chronic migraine.

Do CGRP medicines have identical dosing?

No. Oral gepants and injected/infused antibodies have different schedules, metabolism and interactions.

References

  1. National Institute for Health and Care Excellence. Headaches in over 12s: diagnosis and management. CG150 [Internet]. Updated 2025 Jun 3 [cited 2026 Nov 9]. Available from: https://www.nice.org.uk/guidance/cg150/chapter/Recommendations
  2. International Headache Society. ICHD-3: 1.3 Chronic migraine [Internet]. [cited 2026 Nov 9]. Available from: https://ichd-3.org/1-migraine/1-3-chronic-migraine/
  3. International Headache Society. ICHD-3: 8.2 Medication-overuse headache [Internet]. [cited 2026 Nov 9]. Available from: https://ichd-3.org/8-headache-attributed-to-a-substance-or-its-withdrawal/8-2-medication-overuse-headache-moh/
  4. DailyMed. Sumatriptan tablets: prescribing information [Internet]. Revised 2026 May [cited 2026 Nov 9]. Available from: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e90b0eea-c424-4f00-98da-6ed6e80de1f6
  5. Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A; American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333-41. doi:10.1111/head.14692. Available from: https://pubmed.ncbi.nlm.nih.gov/38466028/
  6. DailyMed. Qulipta (atogepant): prescribing information [Internet]. [cited 2026 Nov 9]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c8ab8f4-32bd-497a-befa-70c8a51d8d52
  7. DailyMed. Nurtec ODT (rimegepant): prescribing information [Internet]. [cited 2026 Nov 9]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d
  8. DailyMed. Vyepti (eptinezumab-jjmr): prescribing information [Internet]. [cited 2026 Nov 9]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=79065861-6aa5-4d1f-829f-3a6471286b36
  9. European Academy of Neurology. European Academy of Neurology guidelines on the treatment of cluster headache. Eur J Neurol. 2023. doi:10.1111/ene.15956. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/ene.15956
  10. Medicines and Healthcare products Regulatory Agency. Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme [Internet]. 2024 Jun 20 [cited 2026 Nov 9]. Available from: https://www.gov.uk/drug-safety-update/topiramate-topamax-introduction-of-new-safety-measures-including-a-pregnancy-prevention-programme
  11. Potrebic S, Tanveer S, Becker WJ, et al. Pharmacologic treatment for migraine prevention in adults practice guideline recommendations: report of the AAN Guidelines Subcommittee and the American Headache Society. Headache. 2026;66(9):2173–2184. doi:10.1111/head.70199. PubMed.

⚠️ Medical Disclaimer

This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.

The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *